---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-030561"
form_type: "8-K"
ticker: "ALXO"
cik: "0001810182"
company_name: "ALX ONCOLOGY HOLDINGS INC"
filed_at: "2026-01-30T23:59:59+00:00"
generated_at: "2026-05-16T06:03:02.720711+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ALX reports $48.3M cash; CD47 predictive of evorpacept response in HER2+ breast cancer Phase 1b/2

## Summary
- Preliminary cash, cash equivalents, and investments total $48.3M as of Dec 31, 2025.
- Phase 1b/2 trial data show CD47 expression is predictive of evorpacept response in HER2+ metastatic breast cancer.
- In 9 confirmed HER2+ patients, cORR was 56% (5/9) with median PFS of 7.4 months (prior SABCS2024 data).
- Full biomarker analysis submitted for presentation at an upcoming scientific conference.
- Results align with ASPEN-06 gastric cancer trial, strengthening confidence in ongoing ASPEN-09-Breast Phase 2 trial.

## SEC filing metadata
- accession: 0001193125-26-030561
- form_type: 8-K
- ticker: ALXO
- cik: 0001810182
- company_name: ALX ONCOLOGY HOLDINGS INC
- filed_at: 2026-01-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810182/000119312526030561/0001193125-26-030561-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810182/000119312526030561/d68428d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-030561
- JSON: https://secwatch.observer/filing/0001193125-26-030561.json
- Plain text: https://secwatch.observer/filing/0001193125-26-030561.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.